General Management

Diana Harbort

Executive Director – CEO

Diana Harbort, U.S. national, resident in Scottsdale (AZ), United States, Chief Executive Officer of Cassiopea. See "The Board of Directors".

Dr. Hans Christoph Tanner

Chief Financial Officer & Head of Investor Relations

Hans Christoph Tanner, Swiss national, resident in Horgen (Zurich), Switzerland, Chief Financial Officer and Head of Investor Relations, has been the CFO of Cassiopea since 2015. Since 2006 he has been a Board Member and CFO of Cosmo Pharmaceuticals SpA now SA. He is also a member of the board of directors or advisory board (Beirat) of DKSH AG (SIX: DKSH), Private Equity Holding AG (SIX: PEH), Qvanteq AG and Joimax GmbH. From 1998 to 2001 he was a partner of Dr. Ernst Mueller-Moehl and co-founder of the 20 Minutes group of newspapers, founded A&A Active Investor, a SIX listed investment company. From 1992 to 1998 he was the head of corporate finance & capital markets of UBS in Zurich and from 1976 to 1991 he had various functions in the Corporate Banking Department of UBS in Zurich, Madrid and Los Angeles. Dr. Tanner has a PhD in economics and diploma as an economist from the University of St. Gallen.

Dr. Luigi Moro

Chief Scientific Officer

Luigi Moro, Italian national, resident in Cairate, Italy, has been chief scientific officer of Cosmo since 2001. He graduated in chemistry and pharmacology at the University of Milan, Italy. He began his career in 1976 with Farmitalia – Carlo Erba, working on discovery/preclinical phase technological projects and the development of new drug administration systems, with particular concentration on anticancer drugs. From 1985 to 1988, with Recordati Industria Chimica e Farmaceutica S.p.A., he collaborated on the direction of technological projects of the parent company and in the definition of drug delivery systems developed by the subsidiary company Pharmetrix, a Californian company specializing in the application of polymer membranes and control systems for problems relating to the controlled administration of drugs. He was appointed manager of the pharmaceutical technology laboratories of Poli Industria Chimica S.p.A. in 1988 and from 1990 to 1995, he coordinated that company’s research activities and industrial applications in the pharmaceutical, synthesis and fermentation sector. In 1996, he became manager of industrial development, responsible for the identification of the technical resources and facilities for the industrial implementation of development projects. He is the author of numerous scientific publications and papers and inventor of numerous international technology patents. He joined Cosmo in 1999.

Alessandro Mazzetti

Chief Medical Officer

Alessandro Mazzetti, Italian (born 1952), CMO since January 1, 2017. From 1 January 2014 he was the Medical Director and since 1 April 2014 Chief Medical Officer of Cosmo Pharmaceuticals. He has extensive experience in clinical trials having managed clinical trials at Smith Kline Beecham (1993–1996) and RBM Serono (1996–2001). Thereafter he worked as a consultant and advisor, amongst other to Cosmo. He graduated in medicine and surgery from Florence University in 1980.

Delivered by Investis – link to website (opens in a new window)